Intensity Therapeutics, Inc. Share Price
Equities
INTS
US45828J1034
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.925 USD | 0.00% | +1.16% | -54.20% |
03-14 | Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-03 | Intensity Therapeutics Gets FDA Green Light for Phase 3 Study | DJ |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 53.81M 4.31B |
---|---|---|---|---|---|
Net income 2024 * | -9M -720M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.27
x | P/E ratio 2025 * |
-
| Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.87% |
1 week | +1.16% | ||
Current month | -24.52% | ||
1 month | -26.36% | ||
3 months | -13.73% | ||
6 months | +24.21% | ||
Current year | -54.20% |
Managers | Title | Age | Since |
---|---|---|---|
Lewis Bender
CEO | Chief Executive Officer | 65 | 31/12/11 |
Joseph Talamo
DFI | Director of Finance/CFO | 55 | 12-10 |
John Wesolowski
AUD | Comptroller/Controller/Auditor | 65 | 28/02/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Goldberg
BRD | Director/Board Member | 64 | 30/04/18 |
Lewis Bender
CEO | Chief Executive Officer | 65 | 31/12/11 |
Emer Leahy
BRD | Director/Board Member | 58 | 31/05/16 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 3.925 | 0.00% | 8,191 |
25/04/24 | 3.925 | -1.63% | 2,986 |
24/04/24 | 3.99 | -1.48% | 4,071 |
23/04/24 | 4.05 | +3.85% | 8,992 |
22/04/24 | 3.9 | +0.52% | 7,107 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.20% | 53.81M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- INTS Stock